<DOC>
	<DOCNO>NCT02738138</DOCNO>
	<brief_summary>The purpose study assess efficacy safety ABT-493/ABT-530 adult chronic hepatitis C virus genotype 1-6 infection human immunodeficiency virus-1 co-infection .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Experimental Drugs ABT- 493/ABT-530 Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection Human Immunodeficiency Virus -1 Coinfection ( EXPEDITION-2 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>1 . Male female , least 18 year age time Screening . 2 . Screening laboratory result indicate HCV GT1 , 2 , 3 , 4 , 5 , 6infection . 3 . Subject positive antiHCV Ab plasma HCV RNA viral load great equal 1000 IU/mL Screening visit . 4 . Subjects must HCV treatmentnaïve ( i.e. , subject never receive single dose approve investigational antiHCV medication ) HCV treatmentexperienced ( subject fail prior IFN pegIFN without RBV , SOF plus RBV without pegIFN ) . GT3 subject must HCV treatmentnaïve . Previous HCV treatment must complete great equal 2 month prior Screening . 5 . Subjects naïve ART must CD4+ count great equal 500 cells/mm^3 ( CD4+ % great equal 29 % ) Screening ; Subjects stable ART regimen must CD4+ count great equal 200 cells/mm^3 ( CD4+ % great equal 14 % ) Screening ; Plasma HIV1 RNA LLOQ Screening least 12 month prior Screening . 1 . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator . 2 . Positive test result Screening hepatitis B surface antigen ( HBsAg ) . 3 . Positive Human Immunodeficiency virus , type 2 ( HIV2 ) Ab Screening . 4 . Receipt investigational commercially available direct act antiHCV agent sofosbuvir ( e.g. , telaprevir , boceprevir , simeprevir , paritaprevir , grazoprevir , daclatasvir , ledipasvir , ombitasvir , elbasvir dasabuvir ) . 5 . Consideration investigator , reason , subject unsuitable candidate receive ABT493/ABT530 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HCV Genotype 3</keyword>
	<keyword>Non-cirrhotic</keyword>
	<keyword>HCV Genotype 1</keyword>
	<keyword>HCV Genotype 6</keyword>
	<keyword>Human Immunodeficiency Virus ( HIV ) Infection</keyword>
	<keyword>HCV Genotype 5</keyword>
	<keyword>HCV Treatment Naive</keyword>
	<keyword>HCV Genotype 4</keyword>
	<keyword>HCV Treatment Experienced</keyword>
	<keyword>HCV Genotype 2</keyword>
	<keyword>Hepatitis C Virus ( HCV ) Infection</keyword>
	<keyword>Compensated Cirrhosis</keyword>
</DOC>